Martínez-Abundis E, Kam-Ramos AM, González-Ortiz M, Robles-Cervantes JA, Ontiveros-Godínez T, Olazábal-Esguerra A, Hernández-Salazar E, Llamas-Moreno JF

Language: Spanish
References: 24
Page: 127-130
PDF size: 267.22 Kb.

ABSTRACT

Background: Heart failure (HF) is a frequent chronic disease characterized by a heart’s pumping inability. There is controversy regarding to changes in leptin and pro-inflammatory cytokines levels in HF, as well as, the compromising of myocardial contractility by insulin sensitivity decreased. The aim of this study was to determine the association of left ventricular ejection fraction (LVEF) with leptin, tumor necrosis factor alpha (TNF-α) and insulin resistance in patients with HF. 1
Material and methods: A cross-sectional study was conducted in 19 HF patients and in 19 healthy volunteers. In all of them, LVEF, cardiac anatomical wholeness and functional class were evaluated; besides, leptin, TNF-α, glucose, creatinine, uric acid, insulin and lipid profile were measured, as well as, insulin resistance by homeostasis model assessment (HOMA-RI) was estimated. Statistical analyses were calculated with Student's t and Pearson's tests.
Results: In HF group predominated the functional class II (37%). HF patients in comparison with the control group showed, greater creatinine and uric acid concentrations, as well as, smaller high-density-lipoprotein cholesterol levels and a tendency to be greater the glucose concentrations. There were no significant correlations of LVEF with leptin, TNF-α and HOMA-RI in both groups.
Conclusions: LVEF was not associated with leptin, TNF-α and insulin resistance in HF patients.

REFERENCES

1. Dalzell JR, Jackson CE. Novel neurohormonal insights with therapeutic potential in chronic heart failure. Future Cardiol 2010;6:361-372.

2. Tang WH, Shrestha K, Van Lente F, Troughton RW, et al. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol 2008;101:370-373.

3. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, et al. Inflammatory markers and incident heart failure risk in older adults the Health ABC (Health, Aging and Body Composition) study. J Am Coll Cardiol 2010;11:2129-2137.

4. Toth MJ, Gottlieb SS, Fisher ML, Ryan AS, et al. Plasma leptin concentrations and energy expenditure in heart failure patients. Metabolism 1997;46:450-453.

5. Filippatos GS, Tsilias K, Venetsanou K, Karambinos E, et al. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int J Cardiol 2000;76:117-122.

6. Abe Y, Ono K, Kawamura T, Wada H, et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 2007;292: H2387-2396.

7. Leyva F, Godsland IF, Ghatei M, Proudler AJ, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998;18:928-933.

8. Swan JW, Walton C, Godsland IF, Clark AL, et al. Insulin resistance in chronic heart failure. Eur Heart J 1994;15:1528-1532.

9. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000;85:4426-4433.

10. Rosamond W, Flegal K, Friday G, Furie K, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.

11. Milo-Cotter O, Adams KF, O'Connor CM, Uriel N, et al. Acute heart failure associated with high admission blood pressure - a distinct vascular disorder? Eur J Heart Fail 2007;9:178-183.

12. Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006;151:76-83.

13. Ruggiero C, Cherubini A, Ble A, Bos AJ, et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174-1181.

14. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006;47:222-229.

15. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, Vooletich MT, et al. Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest 1999;115:1170-1174.

16. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.

17. Anker SD, Ponikowski PP, Clark AL, Leyva F, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683-693.

18. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in «cachectic» patients with severe chronic heart failure. Br Heart J 1991;66:356-358.

19. Wisniacki N, Taylor W, Lye M, Wilding JP. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005;91:32-37.

20. Paternostro G, Camici PG, Lammerstma AA, Marinho N, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 1996; 98:2094-2099.